Microtubule inhibitors

Microtubule inhibitors

Modulo 3 BPT

Modulo 3 BPT

Nuclear structure
DNA structure
Transcription of DNA
Translation of mRNA
Gene regulation
Epigenetics
Amino acids and protein folding
Protein structure and synthesis
Nucleotide metabolism
DNA replication
Lac operon
DNA damage and repair
Cell cycle
Mitosis and meiosis
DNA mutations
Lesch-Nyhan syndrome
Orotic aciduria
Adenosine deaminase deficiency
Xeroderma pigmentosum
Li-Fraumeni syndrome
Bloom syndrome
Fanconi anemia
McCune-Albright syndrome
Acute radiation syndrome
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Gel electrophoresis and genetic testing
ELISA (Enzyme-linked immunosorbent assay)
Karyotyping
DNA cloning
Fluorescence in situ hybridization
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
Inheritance patterns
Independent assortment of genes and linkage
Evolution and natural selection
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Beckwith-Wiedemann syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Familial hypercholesterolemia
Hereditary spherocytosis
Marfan syndrome
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Gaucher disease (NORD)
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Hemochromatosis
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Krabbe disease
Leukodystrophy
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Primary ciliary dyskinesia
Phenylketonuria (NORD)
Sickle cell disease (NORD)
Tay-Sachs disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
Alport syndrome
X-linked agammaglobulinemia
Fabry disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Muscular dystrophy
Ornithine transcarbamylase deficiency
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review
Blood histology
Blood components
Erythropoietin
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Iron deficiency anemia
Sideroblastic anemia
Anemia of chronic disease
Lead poisoning
Hemolytic disease of the newborn
Autoimmune hemolytic anemia
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Aplastic anemia
Megaloblastic anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Diamond-Blackfan anemia
Acute intermittent porphyria
Porphyria cutanea tarda
Vitamin K deficiency
Bernard-Soulier syndrome
Glanzmann's thrombasthenia
Hemolytic-uremic syndrome
Immune thrombocytopenia
Thrombotic thrombocytopenic purpura
Von Willebrand disease
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Antithrombin III deficiency
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antiphospholipid syndrome
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Langerhans cell histiocytosis
Mastocytosis (NORD)
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Prostate cancer
Benign prostatic hyperplasia
Testicular cancer
Ovarian surface epithelial tumors
Ovarian germ cell tumors
Ovarian sex-cord stromal tumors
Endometrial cancer
Cervical cancer
Breast cancer
Disorders of sex chromosomes: Pathology review
Testicular tumors: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Breast cancer: Pathology review
Colorectal cancer
Carcinoid syndrome
Irritable bowel syndrome
Colorectal polyps and cancer: Pathology review
Seizures and epilepsy
Dementia: Pathology review
Movement disorders: Pathology review
Demyelinating disorders: Pathology review
Neuromuscular junction disorders: Pathology review
Adult brain tumors: Pathology review
Inflammatory bowel disease: Pathology review
Bowel obstruction

Transcript

Watch video only

Microtubule inhibitors, as their name implies, disrupt the microtubules and inhibit mitosis, which is a specific phase of the cell cycle.

Anticancer agents in this class include the vinca alkaloids and the taxanes.

But first things first.

The cytoskeleton is a network of proteins within the cell that gives each cell its shape, and it anchors organelles in place.

But it’s also a dynamic network, which can change shape when the cell wants to move, contract, divide, or pull in or push out molecules.

It’s made up of three proteins: actin filaments, intermediate filaments, and microtubules.

Microtubules are made of alternating round proteins called α- and β-tubulins, which form long strands called protofilaments.

Thirteen of these protofilaments come together to form a single microtubule.

Microtubules play a super important role in cell division.

During cell division there are two centrosomes inside the cell, and each centrosome is made out of two centrioles.

Each centriole is in turn made up of nine sets of microtubule triplets.

Now cell division, or mitosis, can be divided into four subphases: prophase, metaphase, anaphase, and telophase.

During prophase, the membrane around the nucleus disintegrates, and the chromosomes condense.

During metaphase, chromosomes move towards the middle of the cell, on a line called the metaphase plate.

Each chromosome is made up of a pair of sister chromatids which are joined together in the centromere where there’s a specific protein complex called the kinetochore.

When the chromosomes are in place, each centrosome sends out thread-like projections called spindle fibers, that attach to the centromere of each chromosome.

Spindle fibers consist of microtubules that originate from the centrioles and polymerize in the direction of the kinetochores.

Next, during anaphase, the centrosomes start pulling on the spindle fibers to pull the sister chromatids apart, forming the mitotic spindle.

It looks a bit like a fishing line being cast out to its target, and then the line gets reeled in, pulling the kinetochore and it’s attached sister chromatid away from its partner chromosome.

Finally, there’s the telophase during which a nuclear membrane forms around each new set of 46 single-chromatid chromosomes.

After that, during cytokinesis, the cell membrane pinches in until the two daughter cells separate.

Alright, now cancer cells replicate rapidly so they are constantly undergoing mitosis and the microtubules are always at work.

This means that microtubule inhibitors will affect these cells more than our healthy cells, most of which only divide occasionally.

Interfering with the formation of microtubules will cause mitosis to fail and the cell will eventually die without replicating.

The two commonly used anticancer microtubule inhibitors include the vinca alkaloids and the taxanes.

All anticancer microtubule inhibitors are given intravenously.

Okay, let’s start with vinca alkaloids, which include vinblastine, and vincristine.

Vinca alkaloids bind to β-tubulin and block its polymerization into protofilaments, which form microtubules, centrioles, centrosomes, and spindle fibers.

This means the cell can’t form stable mitotic spindles and will stop at metaphase.

So, vinca alkaloids act in the M phase of the cell-cycle and are cell-cycle specific.

Moving on to indications.

Vinca alkaloids are used for solid tumors like: breast cancer; pediatric tumors like rhabdomyosarcoma and nephroblastoma or Wilms tumor; and leukemias.

Now, vincristine and vinblastine are both used for Hodgkin’s and non-Hodgkin’s lymphoma.

Let’s move on to side effects.

Vinca alkaloids disrupt the progression of mitosis in all rapidly dividing cells in the body including hair follicles and gastrointestinal epithelium, so vinblastine and vincristine cause alopecia, or loss of hair, and gastrointestinal symptoms.

In addition, they are associated with bone marrow suppression since the cells here are constantly making the platelets, red, and white blood cells.

Now, vinblastine causes more bone marrow suppression, but vincristine is more neurotoxic as it interferes with microtubule polymerization in neuronal axons disrupting the neuronal activity.

Neurotoxicity usually manifests as peripheral neuropathy causing symptoms like a decrease in sensation in the toes and fingers, sometimes called a glove and stocking distribution, as well as autonomic nervous system malfunction with orthostatic hypotension, urinary retention, and constipation.

Alright, next are the taxanes, which are also alkaloid derivatives, and include paclitaxel and docetaxel.

Taxanes also act on microtubules, but they act differently from vinca alkaloids.

Key Takeaways

Microtubules are a component of the cytoskeleton which are involved in cellular transport and cell division. Microtubule inhibitors work by disrupting the function of microtubules, which stops or slows down cell division and movement. This can be useful in cancer treatment, as it can stop or slow down the spread of cancer cells. Some common microtubule inhibitors include paclitaxel (Taxol) and vincristine.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "A microtubule bestiary: structural diversity in tubulin polymers" Molecular Biology of the Cell (2017)
  5. "Cell division: The renaissance of the centriole" Current Biology (1999)
  6. "Cancer Management" UBM Medica (2008)
  7. "Mechanism of taxane neurotoxicity" Breast Cancer (2004)
  8. "Docetaxel" Drugs (2005)